Here are the DEF 14A proxy statements from United Therapeutics Corp (UTHR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow UTHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTHR filings page.
United Therapeutics Corporation calls a virtual 2026 annual shareholder meeting on June 26, 2026 to vote on electing 12 directors, an advisory “Say‑on‑Pay” resolution, approval of the 2026 Stock Incentive Plan, and ratification of Ernst & Young LLP as independent auditor.
The company highlights strong 2025 results, including 11% revenue growth, a 42% net income margin, 56% EBITDASO margin, and 38% total shareholder return, alongside $1.0 billion returned via an accelerated share repurchase. Management emphasizes its pay‑for‑performance design, with 91.1% of CEO pay and 83.6% of other named executive officer pay performance‑based, and its public benefit mission focused on pulmonary hypertension therapies, organ manufacturing, and clinical progress with ralinepag, nebulized Tyvaso for pulmonary fibrosis, and the UKidney xenotransplantation trial.